Compare NEON & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEON | PHIO |
|---|---|---|
| Founded | 1997 | 2003 |
| Country | Sweden | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8M | 12.9M |
| IPO Year | 1994 | 2011 |
| Metric | NEON | PHIO |
|---|---|---|
| Price | $0.89 | $1.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 46.6K | ★ 102.7K |
| Earning Date | 11-11-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.88 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,108,000.00 | N/A |
| Revenue This Year | $69.35 | N/A |
| Revenue Next Year | $28.95 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.72 | $0.81 |
| 52 Week High | $3.81 | $4.19 |
| Indicator | NEON | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 54.53 | 39.67 |
| Support Level | $0.83 | $0.98 |
| Resistance Level | $0.95 | $1.12 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 61.40 | 10.30 |
Neonode Inc provides software solutions for machine perception that feature machine learning algorithms to detect and track persons and objects in video streams from cameras and other types of imagers. Its machine perception solutions are based on the MultiSensing technology platform. The company also offers optical sensing solutions for contactless touch and gesture sensing. It markets and sells its solutions mainly to customers in the automotive sector, along with other markets such as office equipment, industrial automation, medical, military, and avionics. Geographically, the company operates in Japan, South Korea, Germany, Sweden, China, and other regions, with a majority of its revenue generated from Japan.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.